METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to reverse liver damage in MASH cirrhosis
Disease control Recruiting nowThis Phase 3 study tests an experimental drug called pegozafermin in 762 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. Participants receive weekly injections of the drug or a placebo for about two years. The goal is to see if the drug can improve l…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug miricorilant tested for fatty liver disease safety
Knowledge-focused Recruiting nowThis early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC